Morgan Stanley’s RenovoRx RNXT Stock Holding History

Morgan Stanley’s Portfolio RNXT Stock Details RNXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.96K	Hold	7,102	–	–	﹤0.01%	7139
2026 Q1	$7.17K	Buy	7,102 +5,981	+534%	+$5.79K	﹤0.01%	7043
2025 Q4	$942	Buy	+1,121	New	+$1.12K	﹤0.01%	7383
2023 Q4	–	Sell	-176	Closed	-$234	–	7895
2023 Q3	$234	Hold	176	–	–	﹤0.01%	7374
2023 Q2	$398	Hold	176	–	–	﹤0.01%	7398
2023 Q1	$613	Sell	176 -152	-46%	-$535	﹤0.01%	7411
2022 Q4	$771	Sell	328 -100	-23%	-$191	﹤0.01%	7507
2022 Q3	$1K	Sell	428 -1,200	-74%	-$2.61K	﹤0.01%	7594
2022 Q2	$3K	Sell	1,628 -2,224	-58%	-$4.54K	﹤0.01%	7523
2022 Q1	$11K	Buy	+3,852	New	+$13.5K	﹤0.01%	7379

Other funds holding RNXT

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CPIG

Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Morgan Stanley's RNXT Position: Q2 2026 in Review

Morgan Stanley held its RenovoRx (RNXT) position steady in Q2 2026 at 7,102 shares worth $6.96K. The position accounts for ﹤0.01% of the portfolio, ranked #7139.

Morgan Stanley first reported a position in RNXT in Q1 2022 and has held it in 10 quarters since. The position peaked at $11K in Q1 2022. 28 funds tracked by Wall St. Rank hold RNXT as of Q2 2026.

Morgan Stanley held 7,102 shares of RenovoRx worth $6.96K as of Q2 2026.
Morgan Stanley left its RenovoRx share count unchanged in Q2 2026.
RenovoRx made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7139 holding.
Morgan Stanley first reported a position in RenovoRx in Q1 2022 and has held it in 10 quarters since.
Morgan Stanley's RenovoRx position peaked at $11K in Q1 2022.
28 funds tracked by Wall St. Rank held RenovoRx as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.